Publications in collaboration with researchers from Hospital Universitario Central de Asturias (153)

2024

  1. Cardiac events after allo-HCT in patients with acute myeloid leukemia

    Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509

  2. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703

  3. Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions

    Acta Biomaterialia, Vol. 177, pp. 132-147

  4. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  5. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

    HemaSphere, Vol. 8, Núm. 12

  6. Measurement of GFAP in Nasal Exudate in the Differential Diagnosis between Ischemic Stroke and Intracerebral Hemorrhage

    Cerebrovascular Diseases, Vol. 53, Núm. 5, pp. 515-518

  7. Nasal exudate for diagnosis of stroke: fundamental studies through iron fractionation, total iron, and targeted protein determinations

    Analytical and Bioanalytical Chemistry, Vol. 416, Núm. 24, pp. 5365-5375

  8. Next-generation sequencing reveals that miR-16-5p, miR-19a-3p, miR-451a, and miR-25-3p cargo in plasma extracellular vesicles differentiates sedentary young males from athletes

    European Journal of Sport Science, Vol. 24, Núm. 6, pp. 766-776

  9. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  10. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  11. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

    Haematologica, Vol. 109, Núm. 12, pp. 4056-4066